{"transactions":[{"id":730656,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-22T20:15:16.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":3.62,"expiration_date":"2036-06-17","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001995535-26-000008","document":"form4-06222026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000199553526000008/form4-06222026_040610.xml","form_type":"4"}},{"id":930112,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-27T23:45:33.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":38823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from January 23, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of\nshareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":38823,"derivative":{"exercise_price":6.36,"expiration_date":"2036-01-23","underlying":"Class A Ordinary Shares","underlying_shares":38823},"source":{"system":"sec-edgar","filing":"0001995535-26-000006","document":"form4-01272026_110130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000199553526000006/form4-01272026_110130.xml","form_type":"4"}},{"id":1012416,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T18:30:23.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":18.73,"underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001995535-25-000003","document":"form4-10282025_061019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000199553525000003/form4-10282025_061019.xml","form_type":"4"}},{"id":1012415,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T18:30:23.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.91,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001995535-25-000003","document":"form4-10282025_061019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000199553525000003/form4-10282025_061019.xml","form_type":"4"}},{"id":1012414,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T18:30:23.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":9.46,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001995535-25-000003","document":"form4-10282025_061019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000199553525000003/form4-10282025_061019.xml","form_type":"4"}},{"id":1012413,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-28T18:30:23.000Z","date":"2025-10-28","kind":"other","planned":false,"acquired":false,"shares":83782,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001995535-25-000003","document":"form4-10282025_061019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000199553525000003/form4-10282025_061019.xml","form_type":"4"}},{"id":1119088,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T16:38:51.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16800,"derivative":{"exercise_price":18.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001827506-25-000082","document":"wk-form4_1749242295.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000182750625000082/wk-form4_1749242295.xml","form_type":"4"}},{"id":1335860,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-12-11T21:45:10.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":117000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":117000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-12-09","underlying":"Class A Ordinary Shares","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001415889-24-028973","document":"form4-12112024_041205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924028973/form4-12112024_041205.xml","form_type":"4"}},{"id":1349590,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-11-27T21:15:12.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":1001633,"price":2.73,"value":2734458.09,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were disposed of by way of a private transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Athanor Master Fund, LP (the \"Master Fund\") and Athanor International Master Fund, LP (the \"International Master Fund\", and together with the Master Fund, the \"Funds\") are the direct holders of the securities reported herein. Athanor Capital Partners, LP (\"Master GP\") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC (\"ACP GP\") is the general partner of Master GP. Athanor International Fund GP, LP (\"International Master GP\") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC (\"AIFU GP\") is the general partner of International Master GP. Athanor Capital, LP (\"Athanor Capital\") is the investment adviser to the Funds. Athanor Capital GP, LLC (\"Athanor Capital GP\") is the general partner of Athanor Capital. Parvinder Thiara is the managing member of  Athanor Capital GP, AIFU GP and ACP GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in footnote 2 above may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-027847","document":"form4-11272024_041107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924027847/form4-11272024_041107.xml","form_type":"4"}},{"id":1407767,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-09-13T20:15:20.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":3800000,"price":2.7,"value":10260000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were disposed of by way of a private transaction dated September 11, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Athanor Master Fund, LP (the \"Master Fund\") and Athanor International Master Fund, LP (the \"International Master Fund\", and together with the Master Fund, the \"Funds\") are the direct holders of the securities reported herein. Athanor Capital Partners, LP (\"Master GP\") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC (\"ACP GP\") is the general partner of Master GP. Athanor International Fund GP, LP (\"International Master GP\") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC (\"AIFU GP\") is the general partner of International Master GP. Athanor Capital, LP (\"Athanor Capital\") is the investment adviser to the Funds. Athanor Capital GP, LLC (\"Athanor Capital GP\") is the general partner of Athanor Capital. Parvinder Thiara is the managing member of  Athanor Capital GP, AIFU GP and ACP GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in footnote 2 above may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":1001633,"source":{"system":"sec-edgar","filing":"0001415889-24-023366","document":"form4-09132024_040916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924023366/form4-09132024_040916.xml","form_type":"4"}},{"id":1485985,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T16:02:30.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":13.91,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001827506-24-000052","document":"wk-form4_1717790542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000182750624000052/wk-form4_1717790542.xml","form_type":"4"}},{"id":1669753,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock options","published_at":"2024-01-26T16:30:45.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":48149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on June 22, 2023 and would vest over a period of three years, with each 1/3 on an annual basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on June 22, 2023 and would vest over a period of three years, with each 1/3 on an annual basis."}],"balance_after":48149,"derivative":{"exercise_price":3.98,"expiration_date":"2034-01-24","underlying":"Class A Ordinary Shares","underlying_shares":48149},"source":{"system":"sec-edgar","filing":"0001104659-24-007064","document":"tm244212-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465924007064/tm244212-2_4seq1.xml","form_type":"4"}},{"id":1711119,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-12-14T20:35:26.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":2000000,"price":4,"value":8000000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Athanor Master Fund, LP (the \"Master Fund\") and Athanor International Master Fund, LP (the \"International Master Fund\", and together with the Master Fund, the \"Funds\") are the direct holders of the securities reported herein. Athanor Capital Partners, LP (\"Master GP\") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC is the general partner of Master GP. Athanor International Fund GP, LP (\"International Master GP\") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC is the general partner of International Master GP. Athanor Capital, LP (\"Athanor Capital\") is the investment adviser to the Funds. Athanor Capital GP, LLC is the general partner of Athanor Capital. Parvinder Thiara is the managing member of Athanor Capital Partners GP, LLC, Athanor International Fund Ultimate GP, LLC and Athanor Capital GP, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in this footnote may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":4801633,"source":{"system":"sec-edgar","filing":"0001104659-23-126005","document":"tm2332936-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923126005/tm2332936-1_4seq1.xml","form_type":"4"}},{"id":1734111,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T18:14:25.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":17.31,"value":17310.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.13 to $17.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":83782,"source":{"system":"sec-edgar","filing":"0001209191-23-056126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000120919123056126/doc4.xml","form_type":"4"}},{"id":1754584,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T16:46:06.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":12.12,"value":24240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $12.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":82782,"source":{"system":"sec-edgar","filing":"0001209191-23-053670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000120919123053670/doc4.xml","form_type":"4"}},{"id":1754583,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T16:46:06.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":10.66,"value":53300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":80782,"source":{"system":"sec-edgar","filing":"0001209191-23-053670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000120919123053670/doc4.xml","form_type":"4"}},{"id":1756095,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2023-10-23T20:33:10.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option vest on the earlier of October 23, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":9.46,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-053409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000120919123053409/doc4.xml","form_type":"4"}},{"id":1756094,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":36382,"kind":"person","name":"Thiara Parvinder","position":1,"cik":"0001995535","reported_name":"Thiara Parvinder","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-23T20:33:10.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":75782,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"39,996 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on May 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 950,000 shares of common stock of Tourmaline Bio, Inc. (\"Tourmaline\") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the \"Merger Agreement\") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the \"Merger\"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc."}],"balance_after":75782,"source":{"system":"sec-edgar","filing":"0001209191-23-053409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827506/000120919123053409/doc4.xml","form_type":"4"}}]}